Drs. Owens and Rosmarin discuss an overview of the TRuE-V studies and unmet needs in vitiligo.
Results and Implications From the Open-Label Arm of the TRuE-V Long-Term Extension Phase 3 Study
The key safety and efficacy data of the TRuE-V studies are discussed.
The study design for the TRuE-V long-term extension study is discussed.
Dr. Rosmarin discusses the efficacy data from the TRuE-V long-term extension study.
Key adverse events from the TRuE-V studies are highlighted.
The limitations from the TRuE-V studies are analyzed.
Drs. Owens and Rosmarin discuss payer and provider perspectives from the TRuE-V studies.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
2
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
3
Updated HIV treatment guidelines address payer barriers and add Bixlenvo
4
5 things you should know about the midterms and healthcare
5